ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)

Research output: Contribution to journalShort survey

7 Citations (Scopus)

Abstract

Semagacestat (LY450139) is a novel ?-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.

Original languageEnglish (US)
Pages (from-to)533-534
Number of pages2
JournalACS Chemical Neuroscience
Volume1
Issue number8
DOIs
StatePublished - Aug 18 2010

Fingerprint

N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide
Neurosciences
Amyloid Precursor Protein Secretases
Molecules
Phase III Clinical Trials
Alzheimer Disease
Industry

Keywords

  • AD
  • Alzheimer's disease
  • Gamma-secretase
  • LY450139
  • neurodegeneration
  • semagacestat

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

ACS chemical neuroscience molecule spotlight on semagacestat (ly450139). / Hopkins, Corey R.

In: ACS Chemical Neuroscience, Vol. 1, No. 8, 18.08.2010, p. 533-534.

Research output: Contribution to journalShort survey

@article{817b78953b0144f689f2df1eb156114b,
title = "ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)",
abstract = "Semagacestat (LY450139) is a novel ?-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.",
keywords = "AD, Alzheimer's disease, Gamma-secretase, LY450139, neurodegeneration, semagacestat",
author = "Hopkins, {Corey R.}",
year = "2010",
month = "8",
day = "18",
doi = "10.1021/cn1000606",
language = "English (US)",
volume = "1",
pages = "533--534",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on semagacestat (ly450139)

AU - Hopkins, Corey R.

PY - 2010/8/18

Y1 - 2010/8/18

N2 - Semagacestat (LY450139) is a novel ?-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.

AB - Semagacestat (LY450139) is a novel ?-secretase inhibitor currently in late-stage development by Eli Lilly and Company as a potential treatment for Alzheimer's disease (AD). Semagacestat is currently being studied in two phase III clinical trials.

KW - AD

KW - Alzheimer's disease

KW - Gamma-secretase

KW - LY450139

KW - neurodegeneration

KW - semagacestat

UR - http://www.scopus.com/inward/record.url?scp=77955864459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955864459&partnerID=8YFLogxK

U2 - 10.1021/cn1000606

DO - 10.1021/cn1000606

M3 - Short survey

C2 - 22778845

AN - SCOPUS:77955864459

VL - 1

SP - 533

EP - 534

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 8

ER -